- 27 November, 2024
Is it too late to invest in SNAP after shares surged 20% following Q2 results?
After reporting another blockbuster quarter late on Thursday, Snap Inc (NYSE: SNAP) is up about 20% in the stock market this morning. Compared to the
Should you invest in American Express shares after solid Q2 results?
American Express Co. (NYSE:AXP) shares surged 3.44% higher on Friday after the company delivered impressive Q2 results. AXP reported stronger than expected revenue and earnings
Here’s why Credit Suisse sees a 30% upside in Alphabet stock
Mad Money host Jim Cramer said on Friday, “you have to own some big tech stocksâ€, and the brokerages seem to agree. After Citi’s big
Vodafone reiterates full-year outlook as revenue rebounds in Q1
Vodafone Group plc (LON: VOD) said signs of recovery were evident in the fiscal first quarter after a massive hit from the Coronavirus pandemic as
Baird reiterates a “Buy†rating for Boeing while two traders call for caution
Boeing (NYSE: BA) is among the Dow stock that has underperformed this month, but early in the week, they sprung to life following a Baird
Analyst explains why Intel stock is down despite market-beating results
Intel Corp (NASDAQ: INTC) stock slipped about 4% in after-hours trading on Thursday as the company reported market-beating quarterly results, but its future guidance came
Here’s why SNAP jumped about 15% in after-hours trading on Thursday
Snap Inc (NYSE: SNAP) said on Thursday its revenue jumped over 100% in the fiscal second quarter as the advertising market continued to recover. Shares
Unilever tumbles despite half-year earnings beat: should you buy the pullback?
Unilever Plc (LON:ULVR) reported its fiscal half-year results on Thursday before markets opened. The company posted relatively flat revenue growth of 0.03% to €25.79 ($30.36)
Nuveen’s Saira Malik: “it could be another quarter of tough comps for Twitterâ€
Twitter Inc (NYSE: TWTR) reported its financial results for the second quarter on Thursday that beat Wall Street estimates. The company attributed its hawkish performance
Biogen‘s Alzheimer treatment triggers debate regarding its real-world benefits
Biogen (NASDAQ: BIIB) launched in June a new Alzheimer’s disease drug but its uptake so far has been slow, leading one notable Wall Street analyst